ADVFN US – Market Content Editor
-
U.S. Stocks Move Sharply Lower Amid AI Disruption Concerns
After ending Wednesday’s choppy trading session modestly lower, stocks showed a more substantial move to the downside during trading on Thursday. The major averages once again failed to sustain an early upward move and pulled sharply as the day progressed. The major averages saw further downside going into the end of the day, closing near…
-
Crocs soars on earnings beat and upbeat 2026 profit forecast
Crocs (NASDAQ:CROX) shares jumped roughly 15% in premarket trading Thursday after the footwear group delivered a stronger-than-expected fourth quarter and issued an earnings outlook for 2026 that comfortably topped Wall Street forecasts. For the fourth quarter, Crocs reported earnings per share of $2.29, beating the consensus estimate of $1.91. Revenue reached $958 million, exceeding analyst…
-
Tripadvisor shares slide after sharp fourth-quarter earnings miss
Tripadvisor Inc. (NASDAQ:TRIP) shares dropped more than 4% in premarket trading Thursday after the online travel group reported fourth-quarter results that fell well short of Wall Street expectations. The company posted adjusted earnings of $0.04 per share for the quarter, missing analyst forecasts of $0.17. Revenue totaled $411 million, slightly below the consensus estimate of…
-
American Electric Power tops Q4 forecasts, sticks with 2026 profit targets
American Electric Power (NASDAQ:AEP) reported fourth-quarter 2025 operating earnings that beat Wall Street expectations and reiterated its outlook for 2026, sending shares modestly higher in premarket trading. The utility posted operating earnings of $1.19 per share for the quarter, ahead of analyst estimates of $1.14. Revenue climbed to $5.31 billion, comfortably above the $4.99 billion…
-
BioMarin, Ascendis slide as BridgeBio shakes up achondroplasia landscape
Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) and Ascendis Pharma (NASDAQ:ASND) fell roughly 6% after rival BridgeBio Pharma (NASDAQ:BBIO) reported encouraging Phase 3 results for its experimental achondroplasia therapy. BridgeBio said its oral drug infigratinib achieved the primary endpoint in the late-stage PROPEL 3 trial, delivering superior annualized height velocity compared with placebo. The company cited a…
-
BridgeBio rallies on strong Phase 3 data for achondroplasia pill
BridgeBio Pharma (NASDAQ:BBIO) shares climbed about 9% on Thursday after the biotech group unveiled positive Phase 3 topline results for its oral drug infigratinib in achondroplasia, marking what it said were the first statistically significant gains in body proportionality seen in the condition. The late-stage PROPEL 3 study met its primary endpoint, showing that patients…
-
Iron Mountain tops Q4 forecasts, shares gain on strong 2026 outlook
Iron Mountain Incorporated (NYSE:IRM) delivered fourth-quarter results ahead of market expectations, capping a year of record-setting performance and lifting its shares more than 2% in premarket trading on Thursday. The information management and data services group reported adjusted earnings per share of $0.61, edging past analyst estimates of $0.60. Revenue rose 16.6% year over year…
-
Howmet Aerospace guides above Street for Q1, shares rise premarket
Howmet Aerospace (NYSE:HWM) issued a first-quarter outlook that topped Wall Street expectations, sending its shares more than 2% higher in premarket trading on Thursday, as the jet engine components supplier pointed to improving profitability and cash flow in 2026. The upbeat forecast comes as production of popular single-aisle aircraft by Boeing and Airbus continues to…
-
Exelon tops Q4 profit forecasts, unveils upbeat 2026 outlook
Exelon Corporation (NASDAQ:EXC) reported fourth-quarter adjusted earnings ahead of Wall Street estimates on Thursday, even as revenue trailed expectations. Shares rose 0.38% in pre-market trading following the release. The utility group posted adjusted earnings of $0.59 per share for the quarter, beating analyst forecasts of $0.57. Revenue totaled $5.41 billion, missing the $5.51 billion consensus…
-
Kimco Realty tops Q4 forecasts as portfolio occupancy hits record
Kimco Realty (NYSE:KIM) delivered fourth-quarter results ahead of Wall Street expectations, helped by robust leasing momentum and record-high occupancy across its shopping center portfolio. The retail-focused REIT posted earnings per share of $0.21, exceeding analyst estimates by $0.03. Quarterly revenue totaled $542.46 million, above the consensus forecast of $537.32 million. Shares gained 1.05% in after-hours…